Janssen-Cilag International NV, a subsidiary of Johnson & Johnson (JNJ), announced on Friday that the European Commission has approved Balversa or Erdafitinib, as a once-daily oral treatment for adult patients with unresectable or metastatic urothelial carcinoma, with fibroblast growth factor receptor 3.
Henar Hevia, senior director of Oncology at Johnson & Johnson Innovative Medicine, said, "The approval of erdafitinib as a precision therapy further highlights the importance of FGFR testing for all patients with metastatic urothelial cancer, and the need for a multi-disciplinary team approach to optimise outcomes for each patient."
This approval was granted based on findings from Cohort 1 of the Phase 3 THOR study, which demonstrated that erdafitinib reduced the risk of death by 36% compared to chemotherapy.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.